Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
21. |
ECCT/23/05/02 | A5384 A Phase II, Randomized, Open-Label Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents with Tuberculous Meningitis: Improved Management with Antimicrobial AGents Isoniazid rifampiciN LinEzolid for TBM (IMAGINE-TBM) |
Principal Investigator(s) 1. Abraham Siika Site(s) in Kenya 1. Moi University Clinical Research Centre (Uasin Gishu county) 2. KEMRI Walter Reed Project (Kericho county) |
View |
22. |
ECCT/23/05/01 | A5356 A Phase II, Prospective, Randomized, Multicenter Trial to Evaluate the Efficacy and Safety/Tolerability of Two Linezolid Dosing Strategies in Combination with a Short Course Regimen for the Treatment of Drug-Resistant Pulmonary Tuberculosis |
Principal Investigator(s) 1. Abraham Mosigisi Siika Site(s) in Kenya MOI UNIVERSITY CLINICAL RESEARCH CENTRE |
View |
23. |
ECCT/23/03/07 | PLATINUM STUDY (PLATINUM): A multi-part, multi-center PLATform study to assess the efficacy, safety, tolerability and pharmacokinetics of anti-malarial agents administered as monotherapy and/or combination therapy IN patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Godfrey (Site 5001) Allan Otieno 2. Bernhard Ragama Ogutu 3. John (Site 5002) Orimbo Site(s) in Kenya 1. KEMRI Kondele Children Hospital (Kisumu county) 2. AHERO CLINICAL TRIALS UNIT (Kisumu county) |
View |
24. |
ECCT/23/03/01 | Micronutrient supplementation Optimizing nutrient supplementation among pregnant and reproductive age women in Kenya (Virutubisho) |
Principal Investigator(s) 1. DR. Martha Kaeni Mwangome Site(s) in Kenya KILIFI |
View |
25. |
ECCT/23/02/02 | KARISMA An adaptive, randomized, active-controlled, open-label, sequential cohort, multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of intravenous cipargamin (KAE609) in adult and pediatric participants with severe Plasmodium falciparum malaria(KARISMA – KAE609’s Role in Severe Malaria) |
Principal Investigator(s) 1. Simon Kariuki Site(s) in Kenya KEMRI-CGHR, |
View |